Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) - Medical Devices Pipeline Assessment, 2017

Summary

GlobalData's Medical Devices sector report, “Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) - Medical Devices Pipeline Assessment, 2017"" provides an overview of Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

- Extensive coverage of the Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry

Reasons to buy

The report enables you to -

- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product’s current stage of development, territory and estimated launch date

1 Table of Contents 2
1.1 List of Tables 6
1.2 List of Figures 8
2 Introduction 9
2.1 Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) Overview 9
3 Products under Development 10
3.1 Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Stage of Development 10
3.2 Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Territory 11
3.3 Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Regulatory Path 12
3.4 Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Estimated Approval Date 13
3.5 Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) - Ongoing Clinical Trials 14
4 Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) - Pipeline Products under Development by Companies 15
4.1 Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) Companies - Pipeline Products by Stage of Development 15
4.2 Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Stage of Development 16
5 Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) Companies and Product Overview 17
5.1 AnGes MG Inc Company Overview 17
5.1.1 AnGes MG Inc Pipeline Products & Ongoing Clinical Trials Overview 17
5.2 AngioCure, Inc. Company Overview 19
5.2.1 AngioCure, Inc. Pipeline Products & Ongoing Clinical Trials Overview 19
5.3 C. R. Bard Inc Company Overview 20
5.3.1 C. R. Bard Inc Pipeline Products & Ongoing Clinical Trials Overview 20
5.4 Contego Medical, LLC Company Overview 26
5.4.1 Contego Medical, LLC Pipeline Products & Ongoing Clinical Trials Overview 26
5.5 eucatech AG Company Overview 27
5.5.1 eucatech AG Pipeline Products & Ongoing Clinical Trials Overview 27
5.6 M.A. Med Alliance SA Company Overview 28
5.6.1 M.A. Med Alliance SA Pipeline Products & Ongoing Clinical Trials Overview 28
5.7 Medtronic plc Company Overview 31
5.7.1 Medtronic plc Pipeline Products & Ongoing Clinical Trials Overview 31
5.8 Micell Technologies Inc Company Overview 37
5.8.1 Micell Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 37
5.9 QT Vascular Ltd Company Overview 38
5.9.1 QT Vascular Ltd Pipeline Products & Ongoing Clinical Trials Overview 38
5.10 QualiMed Innovative Medizinprodukte GmbH Company Overview 41
5.10.1 QualiMed Innovative Medizinprodukte GmbH Pipeline Products & Ongoing Clinical Trials Overview 41
5.11 SiL Vascular Ltd Company Overview 42
5.11.1 SiL Vascular Ltd Pipeline Products & Ongoing Clinical Trials Overview 42
5.12 SurModics Inc Company Overview 43
5.12.1 SurModics Inc Pipeline Products & Ongoing Clinical Trials Overview 43
5.13 The Spectranetics Corp Company Overview 48
5.13.1 The Spectranetics Corp Pipeline Products & Ongoing Clinical Trials Overview 48
5.14 Vascular Nanotransfer Technologies Company Overview 53
5.14.1 Vascular Nanotransfer Technologies Pipeline Products & Ongoing Clinical Trials Overview 53
6 Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB)- Recent Developments 55
6.1 Jul 11, 2017: Daiichi Sankyo Selected for Ninth Consecutive Year as Constituent of FTSE4Good Global Index by FTSE Russell 55
6.2 Jul 03, 2017: 15th Takamine Memorial Daiichi Sankyo Prize Winner Announced 55
6.3 Jun 27, 2017: Boston Scientific Outlines Strategy for Sustained Growth at 2017 Investor Day 55
6.4 Jun 14, 2017: Spectranetics Announces Election of New Chairperson of the Board of Directors 57
6.5 Jun 08, 2017: B. Braun is participating in the third edition of the High-Tech Founders Fund 58
6.6 May 25, 2017: Medtronic Reports Fourth Quarter and Fiscal Year 2017 Financial Results 58
6.7 May 24, 2017: Medtronic Enrolls First Patient in Study of IN.PACT AV Access Drug-Coated Balloon in Patients with End-Stage Renal Disease 61
6.8 May 03, 2017: Cardiovascular Systems Reports Fiscal 2017 Third-Quarter Financial Results 62
6.9 Apr 27, 2017: Daiichi Sankyo Announces 15 Billion Yen Manufacturing Investment to Support Acceleration of Antibody Drug Conjugate Portfolio 64
6.10 Apr 27, 2017: Boston Scientific Announces Results For First Quarter 2017 65
6.11 Apr 27, 2017: Surmodics Reports Second Quarter Fiscal 2017 Results, Updates Fiscal 2017 Financial Guidance 66
6.12 Apr 27, 2017: Spectranetics Reports First Quarter 2017 Revenue of $69.7 million 67
6.13 Apr 25, 2017: Medtronic Drug-Coated Balloon Demonstrates Consistent Results in Two New Analyses of Complex PAD Patients 67
6.14 Apr 23, 2017: Bard Announces First Quarter Results 68
6.15 Apr 17, 2017: Surmodics Appoints Lisa Wipperman Heine to Its Board of Directors 69
6.16 Apr 12, 2017: Change in the B. Braun Management Board and the Aesculap Management Board 70
6.17 Mar 31, 2017: B. Braun continues its sales and earnings growth 70
6.18 Mar 24, 2017: LifeTech Announces 2016 Annual Results 72
6.19 Mar 13, 2017: Cook Medical Announces Umesh Patel as President of Cook Biotech 74
6.20 Mar 09, 2017: Medtronic Launches Below-The-Knee Clinical Study In Europe For Treatment Of PAD Using New Drug-Coated Balloon Technology 75
6.21 Mar 07, 2017: Anteo Technologies Announces Verification Study With Cook Medical Australia 76
6.22 Feb 24, 2017: Daiichi Sankyo Announces Organizational Restructuring Effective as of April 1, 2017 76
6.23 Feb 24, 2017: Daiichi Sankyo Appoints New Group Corporate Officers 78
6.24 Feb 23, 2017: Spectranetics Reports Fourth Quarter 2016 Revenue of $71.9 million 79
6.25 Feb 22, 2017: Change in the B. Braun Management Board 79
6.26 Feb 21, 2017: Medtronic Reports Third Quarter Financial Results 80
6.27 Feb 21, 2017: Cardiovascular Systems Announces Healthcare Veteran Martha Goldberg Aronson Joins Board of Directors 82
6.28 Feb 20, 2017: LUMINOR Registry may help “reopen the door” for drug-coated balloons below the knee 83
6.29 Feb 15, 2017: Daiichi Sankyo Strengthens Authorized Generic Business through Daiichi Sankyo Espha 83
6.30 Feb 10, 2017: Daiichi Sankyo Announces Further Reorganization of its Research & Development Structure 84
6.31 Feb 09, 2017: Medtronic Announces Health Canada Licence for Drug-Coated Balloon 85
6.32 Feb 09, 2017: First Drug-Coated Balloon Study Results in Japan Demonstrate Consistent Clinical Outcomes with Other Medtronic DCB Studies 85
6.33 Feb 09, 2017: Terumo Announces Change of Executive Officers 86
6.34 Feb 06, 2017: Medtronic Awarded U.S. Department of Veterans Affairs National Contracts for Home Telehealth Technologies, with Three Other Vendors 87
6.35 Feb 02, 2017: Boston Scientific Announces Results For Fourth Quarter And Full Year Ended December 31, 2016 88
6.36 Feb 02, 2017: Surmodics Reports First Quarter Fiscal 2017 Results 89
6.37 Jan 31, 2017: Daiichi Sankyo Announces New Chairman and President 91
6.38 Jan 31, 2017: Terumo Opens a Branch in Yangon 91
6.41 Jan 25, 2017: Medtronic IN.PACT Admiral Drug-Coated Balloon Demonstrates Consistent Results in Asia and Belgium According to New Data Presented at LINC 2017 93
6.42 Jan 25, 2017: LINC 2017: Physicians Discuss Lesion Response-Adapted Therapies for Lower Limb Interventions 94
6.43 Jan 25, 2017: iVascular Official Program Activities at LINC 2017 95
6.44 Jan 25, 2017: Cardiovascular Systems Reports Fiscal 2017 Second-Quarter Financial Results 96
6.45 Jan 24, 2017: ILLUMENATE Global 12-month Results Validate Stellarex’s Top-tier Performance in Complex Patient Populations 98
6.46 Jan 11, 2017: Spectranetics Names Scott Hutton as General Manager, Vascular Intervention 99
6.47 Jan 10, 2017: Daiichi Sankyo Announces Reorganization of Research & Development System 99
6.48 Dec 16, 2016: FDA Grants QT Vascular Full IDE Approval to Begin Pivotal Trial Of Its Drug-Coated Balloon, Chocolate Touch 100
6.49 Dec 12, 2016: Terumo Formulates 5-Year Mid- to Long-term Growth Strategy 100
6.50 Nov 22, 2016: Medtronic Reports Second Quarter Financial Results 101
6.51 Nov 21, 2016: Spectranetics Receives CE Mark for Stellarex 0.014” Drug-Coated Balloon 104
6.52 Nov 16, 2016: Medtronic Releases FY16 Integrated Performance Report 104
6.53 Nov 16, 2016: Surmodics Reports Fourth Quarter Fiscal 2016 Results 105
6.54 Nov 15, 2016: CEVA to work with Medtronic for distribution facility construction 106
6.55 Nov 02, 2016: Spectranetics Files PMA Application for FDA Approval of the Stellarex Drug-Coated Balloon 107
6.56 Nov 02, 2016: Stellarex ILLUMENATE Pivotal Results Are Top-tier in the Most Complex Patient Group Studied in DCB IDE Trials 108
6.57 Oct 31, 2016: Surmodics Announces Launch of Serene Single-Coat (SC) Solutions Offering Unmatched Lubricity and Durability to a Broader Range of Device Applications 109
6.58 Oct 27, 2016: Spectranetics Reports Third Quarter 2016 Revenue of $68.3 million 110
6.59 Oct 26, 2016: Boston Scientific Announces Results For Third Quarter 2016 110
6.60 Oct 26, 2016: Cardiovascular Systems Reports Fiscal 2017 First-Quarter Financial Results 112
6.61 Oct 25, 2016: Bard Announces Third Quarter Results 113
6.62 Oct 10, 2016: Professor Ian Meredith To Join Boston Scientific As Executive Vice President And Global Chief Medical Officer 114
6.63 Sep 19, 2016: QT Vascular Announces FDA Has Granted Approval To Initiate The Pivotal Trial Of Its Novel Drug-Coated Balloon 115
6.64 Sep 19, 2016: New Data Presented in VIVA Late Breaking Clinical Trials Demonstrate Durability, Safety and Efficacy for the Medtronic In.Pact Admiral DCB 116
6.65 Sep 19, 2016: FDA Approves 6-Month Primary End Point For The Lutonix Below-the-Knee Drug Coated Balloon 117
6.66 Sep 15, 2016: Eurocor enters the market with their FREEWAY COATED SHUNT BALLOON CATHETER 118
6.67 Sep 15, 2016: Medtronic Names Mark Ploof Senior Vice President of Global Operations and Business Services 119
6.68 Sep 13, 2016: Medtronic Receives FDA Approval of First Drug-Coated Balloon for Treatment of In-Stent Restenosis 120
6.69 Sep 06, 2016: Daiichi Sankyo Announces New Global Head of Development 121
6.70 Aug 31, 2016: Cook Medical Names Jean-Marc Creissel Vice President of Operations in Greater China 121
6.71 Aug 25, 2016: Medtronic Reports First Quarter Financial Results 122
6.72 Aug 16, 2016: Cardiovascular Systems Names Scott Ward as CEO 125
6.73 Aug 10, 2016: First Randomized Trial of the Stellarex Drug-coated Balloon Presented at the Amputation Prevention Symposium 125
6.74 Aug 03, 2016: Cardiovascular Systems Reports Fiscal 2016 Fourth-Quarter Financial Results 126
6.75 Jul 28, 2016: Spectranetics Reports Second Quarter 2016 Revenue of $67.7 million 128
6.76 Jul 28, 2016: Surmodics Reports Third Quarter Fiscal 2016 Results 128
6.77 Jul 28, 2016: Boston Scientific Announces Results For Second Quarter 2016 130
6.78 Jul 26, 2016: Bard Announces Second Quarter Results 131
6.79 Jul 25, 2016: QT Vascular Announces Federal Circuit Reversal of Adverse AngioScore / Spectranetics Judgment 132
6.80 Jul 21, 2016: Federal Circuit Court Rules in Appeal 133
6.81 Jul 20, 2016: 12-month Results of the ILLUMENATE European Randomized Clinical Trial to be Presented at the Amputation Prevention Symposium 133
7 Appendix 134
7.1 Methodology 134
7.2 About GlobalData 137
7.3 Contact Us 137
7.4 Disclaimer 137